阿达木单抗治疗银屑病的研究进展

Adalimumab in the treatment of psoriasis

银屑病是一种免疫介导的慢性炎症性疾病，对患者的生活质量造成很大影响。阿达木单抗是完全人源化抗肿瘤坏死因子一仅的单克隆抗体，通过拮抗肿瘤坏死因子-α起作用，在美国被批准用于银屑病性关节炎、中重度斑块状银屑病等。阿达木单抗治疗银屑病起效较快、有较高的疗效，无特定的器官毒性、多数患者能够耐受，是一种较有发展前景的药物，但长期使用的安全性需要进一步观察。

Psoriasis is an immune-mediated and chronic inflammatory disease with a great impact on the quality of life. Adalimumab is the first fully human IgG1 monoclonal antibody against tumor necrosis factor （TNF） alpha that has been approved abroad for the treatment of moderate-to-severe plaque-type psoriasis and psoriatic arthritis （PsA）. Adalimumab functions by antagonizing the TNF alpha signaling pathway, and has a rapid onset of action, sustained high efficacy and favorable tolerance with no specific organ toxicity. Hence, adalimumab is a prospective drug. Nevertheless, additional studies are warranted to confirm the long-term safety of adalimumab.